Hypertension: Relationship between calcium channel blockers and the risk of active TB

Iron, an important mineral of intracerine pathogens, reduces the biousing of iron by calcium channel blockers (CBBs).
, it is not clear whether the use of CCCB in clinical practice will alter the risk of active TB.
, a study published in hypertension, an authoritative journal of cardiovascular disease, aims to determine whether CCCB can change the risk of active TB.
researchers conducted a nested case-control study of Taiwan's National Health Insurance Research Database between January 1999 and December 2011 and used conditional Logistic regression and disease risk score adjustments to calculate the risk of active TB associated with CCCB use.
subgroup analysis investigated the effects of different types of CCCBs and the potential impacts of different subgroups.
the study assessed a total of 8,164 new cases of active TB and 816,400 control cases.
the disease risk score, the use of CCCB reduced the risk of active tuberculosis by 32% (relative risk of 0.68 (95% CI is 0.58-0.78).
the risk of TB is lower (RR is 0.63 (95% CI is 0.53-0.79) than using a DH2 CCCB (RR is 0.57-0.94) compared to not using a CCCB.
contrary, the use of β-subject blockers (RR is 0.99 (95% CI is 0.83-1.12)) or diuretics (RR is 0.88 (95% CI is 0.62-1.26)) were not associated with a lower risk of TB.
in subgroup analysis, the risk of tuberculosis associated with CCCB was similar for patients with heart failure or cerebrovascular disease.
, the study confirms that the use of hydrohydrocarbon CCCB can reduce the risk of active TB.
。